Latest News

Autolus Therapeutics aiming for NASDAQ IPO

This April, Autolus Therapeutics and Miltenyi Biotec inked a long-term agreement on the supply and support of Miltenyi Biotec’s CliniMACS Prodigy instruments, reagents and disposables for the manufacture of Autolus’ programmed T cell therapies. © Miltenyi Biotec


by tg

British T cell player, Autolus Therapeutics Ltd. wants to go NASDAQ selling 7.8 million American Depositary Shares (ADSs) at  at least US-$15, totaling in US$117m. Through a greenshoe option, Autolus want to offer additional 1,171,875 ADS at the IPO price. 

Goldman Sachs & Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. Wells Fargo Securities, LLC and William Blair & Company, L.L.C. are acting as lead managers.

The company is well-financed. Last September, Autolus added a US$80m Series C equity funding to US$96m raised in previous financing rounds led by Syncona Ltd., Woodford Investment Management, and Arix Bioscience plc.

Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I) a similar approach to approved CAR-T cell therapies from Novartis and Gilead Sciences, or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate however is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma.

Sanofi buys Synthorx Inc for US$2.35bn

Sanofi SA‘s and Synthorx Inc's Boards approved the deal which forsees that Sanofi will acquire all of the outstanding shares of Synthorx for $68 per...

British diagnostics play OBD lands contract with US pharma

Oxford Biodynamics plc (AIM:OBD) recently presented study results, where researchers profiled blood samples of cancer patients retrospectively...

BioVersys receives up to €8m from CARB-X

Privately-owned BioVersys AG, headquartered in Basel, is focusing on research and development of small molecules for multidrug-resistant bacterial...

Researchers identify viral inflammation switch

Their findings in mice models that were infected with the Influenza A virus may have also impact on further virally induced inflammations,researchers...

Protein protects against liver fibrosis

In mice, a team headed by Philipp Lang from University Düsseldorf, Germany, showed that the iRhom2 protein counteracted the injury- and...

Polyphor presents AMR breaker

In Nature, Anatol Luther et al. from Polyphor AG and the University of Zurich describe the discovery and characterisation of a new class of...

Merck and 4SC collaborate in immunooncology

Under the agreement, 4SC AG will sponsor clinical testing of a combination of its oral class I histone deacetylase (HDAC) blocker domatinostat (HDAC...